Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior ...

Bourla and Shantanu Narayen, Pfizer's lead independent director and Adobe Systems CEO, will hold talks with Starboard chief ...

Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

Pfizer has terminated development of its RSV treatment candidate sisunatovir, a viral inhibitor picked up in its up to $525 ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

Officials are encouraging Connecticut residents to get their updated shots before the holiday season begins. Unlike COVID-19 ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...